Stephen Clarke
Stephen Clarke
Professor of Medicine, University of Sydney and Medical Oncologist, RNSH and Genesis Care
Verified email at sydney.edu.au
Title
Cited by
Cited by
Year
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
LB Saltz, S Clarke, E Díaz-Rubio, W Scheithauer, A Figer, R Wong, ...
Journal of clinical oncology 26 (12), 2013-2019, 2008
33192008
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
J Cassidy, S Clarke, E Díaz-Rubio, W Scheithauer, A Figer, R Wong, ...
Journal of clinical oncology 26 (12), 2006-2012, 2008
9182008
The systemic inflammation-based neutrophil–lymphocyte ratio: experience in patients with cancer
GJK Guthrie, KA Charles, CSD Roxburgh, PG Horgan, DC McMillan, ...
Critical reviews in oncology/hematology 88 (1), 218-230, 2013
8952013
Cancer-related inflammation and treatment effectiveness
CI Diakos, KA Charles, DC McMillan, SJ Clarke
The Lancet Oncology 15 (11), e493-e503, 2014
7732014
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
A de Gramont, E Van Cutsem, HJ Schmoll, J Tabernero, S Clarke, ...
The lancet oncology 13 (12), 1225-1233, 2012
4982012
Clinical pharmacokinetics of docetaxel
SJ Clarke, LP Rivory
Clinical pharmacokinetics 36 (2), 99-114, 1999
4921999
Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer
W Chua, KA Charles, VE Baracos, SJ Clarke
British journal of cancer 104 (8), 1288-1295, 2011
4082011
Regulation of drug metabolizing enzymes and transporters in infection, inflammation, and cancer
ET Morgan, CM Lee, BA Nyagode
Encyclopedia of drug metabolism and interactions, 1-45, 2011
3562011
A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer
MJ Proctor, DC McMillan, DS Morrison, CD Fletcher, PG Horgan, ...
British journal of cancer 107 (4), 695-699, 2012
3412012
High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy
SCH Kao, N Pavlakis, R Harvie, JL Vardy, MJ Boyer, N van Zandwijk, ...
Clinical cancer research 16 (23), 5805-5813, 2010
2782010
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
J Cassidy, S Clarke, E Diaz-Rubio, W Scheithauer, A Figer, R Wong, ...
British journal of cancer 105 (1), 58-64, 2011
2472011
Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy
KA Slaviero, SJ Clarke, LP Rivory
The lancet oncology 4 (4), 224-232, 2003
2402003
Impact of medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: a randomized controlled trial
B Oh, P Butow, B Mullan, S Clarke, P Beale, N Pavlakis, E Kothe, L Lam, ...
Annals of Oncology 21 (3), 608-614, 2010
2372010
Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea
R Sharma, P Tobin, SJ Clarke
The lancet oncology 6 (2), 93-102, 2005
2292005
Cancer patient disclosure and patient-doctor communication of complementary and alternative medicine use: a systematic review
EL Davis, B Oh, PN Butow, BA Mullan, S Clarke
The oncologist 17 (11), 1475, 2012
2282012
The relationship between available support, unmet needs and caregiver burden in patients with advanced cancer and their carers
L Sharpe, P Butow, C Smith, D McConnell, S Clarke
Psycho‐Oncology: Journal of the Psychological, Social and Behavioral …, 2005
2252005
Potential regional differences for the tolerability profiles of fluoropyrimidines
DG Haller, J Cassidy, SJ Clarke, D Cunningham, E Van Cutsem, PM Hoff, ...
Journal of Clinical Oncology 26 (13), 2118-2123, 2008
2242008
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study
N van Zandwijk, N Pavlakis, SC Kao, A Linton, MJ Boyer, S Clarke, ...
The Lancet Oncology 18 (10), 1386-1396, 2017
2212017
Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response
LP Rivory, KA Slaviero, SJ Clarke
British journal of cancer 87 (3), 277-280, 2002
2032002
Phase II trial of pemetrexed disodium (ALIMTA®, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer
SJ Clarke, R Abratt, L Goedhals, MJ Boyer, MJ Millward, SP Ackland
Annals of oncology 13 (5), 737-741, 2002
1922002
The system can't perform the operation now. Try again later.
Articles 1–20